Geode Capital Management LLC bought a new position in shares of Guardant Health Inc (NASDAQ:GH) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 220,229 shares of the company’s stock, valued at approximately $8,278,000. Geode Capital Management LLC owned approximately 0.26% of Guardant Health at the end of the most recent reporting period.
Several other large investors have also bought and sold shares of the company. Benjamin F. Edwards & Company Inc. purchased a new position in Guardant Health during the fourth quarter worth about $26,000. Citigroup Inc. purchased a new position in Guardant Health during the fourth quarter worth about $94,000. Victory Capital Management Inc. purchased a new position in Guardant Health during the fourth quarter worth about $124,000. Pendal Group Ltd purchased a new position in Guardant Health during the fourth quarter worth about $213,000. Finally, Janney Montgomery Scott LLC purchased a new position in Guardant Health during the fourth quarter worth about $220,000. 69.45% of the stock is owned by institutional investors.
Several research firms recently weighed in on GH. Zacks Investment Research cut shares of Guardant Health from a “hold” rating to a “sell” rating in a report on Tuesday, April 9th. Cowen boosted their price target on shares of Guardant Health from $40.00 to $70.00 and gave the stock an “outperform” rating in a report on Wednesday, April 3rd. Bank of America upgraded shares of Guardant Health from a “neutral” rating to a “buy” rating and set a $84.00 price target on the stock in a report on Wednesday, April 10th. JPMorgan Chase & Co. boosted their target price on shares of Guardant Health from $42.00 to $85.00 and gave the company an “overweight” rating in a research note on Wednesday, March 13th. Finally, William Blair reiterated an “outperform” rating on shares of Guardant Health in a research note on Wednesday, March 13th. One investment analyst has rated the stock with a sell rating and five have issued a buy rating to the company’s stock. Guardant Health presently has a consensus rating of “Buy” and an average price target of $79.67.
Guardant Health (NASDAQ:GH) last released its earnings results on Tuesday, March 12th. The company reported ($0.30) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.35) by $0.05. The company had revenue of $32.87 million during the quarter, compared to analysts’ expectations of $24.57 million. As a group, equities research analysts anticipate that Guardant Health Inc will post -1.5 EPS for the current year.
In related news, major shareholder Vision Fund (Aiv M1) Softbank bought 2,033,990 shares of the company’s stock in a transaction on Tuesday, March 12th. The shares were purchased at an average cost of $9.83 per share, for a total transaction of $19,994,121.70. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
TRADEMARK VIOLATION NOTICE: This piece of content was first reported by Ticker Report and is the sole property of of Ticker Report. If you are viewing this piece of content on another domain, it was illegally stolen and reposted in violation of United States and international copyright & trademark laws. The legal version of this piece of content can be read at https://www.tickerreport.com/banking-finance/4296169/geode-capital-management-llc-invests-8-28-million-in-guardant-health-inc-gh.html.
About Guardant Health
Guardant Health, Inc, a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers liquid biopsy tests for advanced stage cancer, such as Guardant360, a molecular diagnostic test that measures various cancer-related genes; and GuardantOMNI, a broader gene panel, including genes associated with homologous recombination repair deficiency and biomarkers for immuno-oncology applications.
Featured Article: Average Daily Trade Volume – ADTV
Receive News & Ratings for Guardant Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardant Health and related companies with MarketBeat.com's FREE daily email newsletter.